Zacks Investment Research Downgrades Wave Life Sciences (NASDAQ:WVE) to Hold

Share on StockTwits

Zacks Investment Research cut shares of Wave Life Sciences (NASDAQ:WVE) from a buy rating to a hold rating in a research note issued to investors on Saturday morning, Zacks.com reports.

According to Zacks, “WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington’s disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington’s disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore. “

Other equities research analysts have also recently issued research reports about the company. HC Wainwright set a $33.00 target price on Wave Life Sciences and gave the stock a buy rating in a research note on Wednesday, October 9th. ValuEngine raised Wave Life Sciences from a hold rating to a buy rating in a research note on Wednesday, October 2nd. Mizuho reaffirmed a buy rating on shares of Wave Life Sciences in a research note on Wednesday, September 25th. Cowen reaffirmed a hold rating on shares of Wave Life Sciences in a research note on Tuesday, July 30th. Finally, BidaskClub cut Wave Life Sciences from a hold rating to a sell rating in a research note on Friday, September 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Wave Life Sciences presently has a consensus rating of Hold and a consensus price target of $49.50.

Wave Life Sciences stock opened at $21.69 on Friday. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $705.15 million, a PE ratio of -4.29 and a beta of 0.75. Wave Life Sciences has a 12 month low of $17.59 and a 12 month high of $50.98. The stock has a 50-day moving average price of $21.51 and a two-hundred day moving average price of $24.54.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Monday, July 29th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.11) by ($0.11). Wave Life Sciences had a negative return on equity of 120.41% and a negative net margin of 861.41%. The company had revenue of $7.63 million for the quarter, compared to the consensus estimate of $15.76 million. As a group, analysts predict that Wave Life Sciences will post -5.41 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new position in Wave Life Sciences during the first quarter valued at approximately $2,317,000. Clear Street Markets LLC acquired a new position in Wave Life Sciences during the second quarter valued at approximately $575,000. Bailard Inc. grew its holdings in Wave Life Sciences by 97.6% during the second quarter. Bailard Inc. now owns 83,000 shares of the company’s stock valued at $2,165,000 after purchasing an additional 41,000 shares during the last quarter. Aperio Group LLC acquired a new position in Wave Life Sciences during the second quarter valued at approximately $51,000. Finally, Janus Henderson Group PLC grew its holdings in Wave Life Sciences by 16.1% during the second quarter. Janus Henderson Group PLC now owns 3,392,298 shares of the company’s stock valued at $88,505,000 after purchasing an additional 470,402 shares during the last quarter. 88.84% of the stock is currently owned by institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

See Also: Why is cost of goods sold important?

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

VIBE  Hits One Day Volume of $199,942.00
VIBE Hits One Day Volume of $199,942.00
Zacks: Analysts Expect WellCare Health Plans, Inc.  Will Post Quarterly Sales of $7.10 Billion
Zacks: Analysts Expect WellCare Health Plans, Inc. Will Post Quarterly Sales of $7.10 Billion
Vision Industry Token Price Reaches $0.0001 on Major Exchanges
Vision Industry Token Price Reaches $0.0001 on Major Exchanges
Po.et   Trading 8.5% Lower  Over Last Week
Po.et Trading 8.5% Lower Over Last Week
$376.23 Million in Sales Expected for Amneal Pharmaceuticals Inc  This Quarter
$376.23 Million in Sales Expected for Amneal Pharmaceuticals Inc This Quarter
Brokerages Anticipate Medtronic PLC  to Post $1.39 EPS
Brokerages Anticipate Medtronic PLC to Post $1.39 EPS


 
© 2006-2019 Zolmax.